Trial Profile
Feasibility and Safety of Avoiding Granulocyte Colony-stimulating Factor Prophylaxis During the Paclitaxel Portion of Dose Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 May 2022
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Cyclophosphamide; Doxorubicin; Pegfilgrastim
- Indications Early breast cancer
- Focus Adverse reactions
- 11 Apr 2022 Status changed from active, no longer recruiting to completed.
- 30 Jun 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.
- 24 Apr 2020 Primary endpoint (Rate of Paclitaxel Treatment Completion) has been met.